Variant Gene Risk Allele Score vda Association Type Original DB Sentence supporting the association PMID PMID Year
dbSNP: rs1001179
rs1001179
CAT
0.010 GeneticVariation BEFREE Furthermore, stratified analyses revealed a significant association between the rs1001179 polymorphism and prostate cancer in all models except the homozygote comparison. 27449288

2016

dbSNP: rs10012
rs10012
0.020 GeneticVariation BEFREE A common C-G-C-C-G-A haplotype for rs2567206-rs2551188-rs2617266-rs10012-rs1056836-rs1800440 showed an inverse association with PCa risk in Hispanic Caucasians (OR = 0.19, P = 0.04, 95% CI = 0.04-0.95) and with aggressive disease status (i.e. 18544568

2008

dbSNP: rs10012
rs10012
0.020 GeneticVariation BEFREE In summary, this meta-analysis suggests that Leu432Val polymorphism is associated with ovarian cancer, lung cancer, and endometrial cancer risk; Asn453Ser and Arg48Gly polymorphisms are associated with endometrial cancer risk among Caucasians, Ala119Ser polymorphism is associated with prostate cancer risk, and Ala119Ser polymorphism is associated with breast cancer risk in Caucasians. 25475389

2015

dbSNP: rs1004072779
rs1004072779
ERG
0.010 GeneticVariation BEFREE Significant association of TMPRSS2-ERG fusion-positive PCa was found with rare variants in the genes for POLI [variant F532S: P = 0.0011; odds ratios (OR), 4.62; 95% confidence interval (95% CI), 1.84-11.56] and ESCO1 (variant N191S: P = 0.0034; OR, 4.27; 95% CI, 1.62-11.28). 19861517

2009

dbSNP: rs10046
rs10046
0.010 GeneticVariation BEFREE The combination of the TTTA long repeats and the minor alleles of rs10046 in CYP19A1 and rs2077647 in ESR-alpha was a high risk for prostate cancer despite greater than or equal to 60 mg isoflavones/day. 19952760

2010

dbSNP: rs10069690
rs10069690
0.010 GeneticVariation BEFREE The T allele of the intron 4 SNP (rs10069690) was found to be significantly associated with a decreased risk for an aggressive form of PCa (OR=0.76; 95% CI: 0.59-0.97; P=0.030). 25738283

2015

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE We showed statistically significant association of the A allele of rs1447295 (OR [CI 95%] = 1.96 [1.37-2.81], P<0.0001) and the T allele of rs10090154 (OR [CI 95%] = 2.14 [1.41-3.26], P<0.0001) with CaP. 23628314

2014

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE We genotyped three variants associated with prostate cancer (rs10090154, rs13254738, and rs7000448), one associated with both prostate and colorectal cancer (rs6983267), and one associated with breast cancer (rs13281615) in a series of 1,499 breast cancer cases and 1,390 controls. 18349290

2008

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE The risk alleles rs16901966, rs1447295 and rs10090154 were associated with age at diagnosis and tumor stage as compared with controls, while rs16901966 was associated with aggressive PCa (OR 1.43, 95% CI 1.01-2.03, p=0.042). 24377597

2014

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE Therefore, this meta-analysis demonstrated that 8q24 polymorphisms (rs6983267 T>G, rs1447295 C>A, rs16901979 C>A, rs6983561 A>C and rs10090154 C>T) were associated with the susceptibility to PCa, which held the potential biomarkers for PCa risk. 29158792

2017

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE Four GWAS replication SNPs (rs2660753, rs13254738, rs10090154, rs2735839) and seven flanking SNPs were associated with CaP aggressiveness (P < 0.05) in three genomic regions: One at 3p12 (EA), seven at 8q24 (5 AA, 2 EA), and three at 19q13 at the kallilkrein-related peptidase 3 (KLK3) locus (two AA, one AA and EA). 22549899

2013

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE For northern Chinese men rs16901966, rs1447295, rs11986220 and rs10090154 at 8q24 (region 1, region 2) are associated with prostate cancer and prostate cancer related clinical covariates. 22099997

2012

dbSNP: rs10090154
rs10090154
0.070 GeneticVariation BEFREE The cumulative effects test of risk alleles (rs rs1983891, rs339331, rs16901966, rs1447295 and rs</span>10090154) showed an increasing risk to PCa in a frequency-dependent manner (ptrend=0.001), and men with more than 3 risk alleles had the most significant susceptibility to PCa (OR=1.99, p=0.001), compared with those who had one risk allele (OR=1.17, p=0.486). 26537068

2016

dbSNP: rs1012477
rs1012477
0.010 GeneticVariation BEFREE Our results showed that at least one SNP in nine core circadian genes (rs885747 and rs2289591 in PER1; rs7602358 in PER2; rs1012477 in PER3; rs1534891 in CSNK1E; rs12315175 in CRY1; rs2292912 in CRY2; rs7950226 in ARNTL; rs11133373 in CLOCK; and rs1369481, rs895521, and rs17024926 in NPAS2) was significantly associated with susceptibility to prostate cancer (either overall risk or risk of aggressive disease), and the risk estimate for four SNPs in three genes (rs885747 and rs2289591 in PER1, rs1012477 in PER3, and rs11133373 in CLOCK) varied by disease aggressiveness. 19934327

2009

dbSNP: rs1016343
rs1016343
T 0.700 GeneticVariation GWASDB Multiple newly identified loci associated with prostate cancer susceptibility. 18264097

2008

dbSNP: rs1016343
rs1016343
0.700 GeneticVariation GWASDB Evaluating genetic risk for prostate cancer among Japanese and Latinos. 22923026

2012

dbSNP: rs1016343
rs1016343
T 0.700 GeneticVariation GWASDB Genome-wide association study identifies new prostate cancer susceptibility loci. 21743057

2011

dbSNP: rs1016343
rs1016343
0.700 GeneticVariation GWASDB Genome-wide testing of putative functional exonic variants in relationship with breast and prostate cancer risk in a multiethnic population. 23555315

2013

dbSNP: rs10165970
rs10165970
0.010 GeneticVariation BEFREE Study distribution by tumor was as follows: breast cancer (n=15), prostate cancer (n=3), pancreatic cancer (n=2), non-Hodgkin's lymphoma (n=2), glioma (n=1), chronic lymphocytic leukemia (n=1), colorectal cancer (n=1), non-small cell lung cancer (n=1) and ovarian cancer (n=1).We identified 10 single nucleotide polymorphisms (SNPs) significantly associated with cancer risk: NPAS2 rs10165970 (mixed and breast cancer shiftworkers), rs895520 (mixed), rs17024869 (breast) and rs7581886 (breast); CLOCK rs3749474 (breast) and rs11943456 (breast); RORA rs7164773 (breast and breast cancer postmenopausal), rs10519097 (breast); RORB rs7867494 (breast cancer postmenopausal), PER3 rs1012477 (breast cancer subgroups) and assessed the level of quality evidence to be intermediate. 28177907

2017

dbSNP: rs10175368
rs10175368
0.010 GeneticVariation BEFREE These results demonstrate smoking and alcohol consumption to modify the risks of CYP1B1 polymorphisms for prostate cancer which may be through rs10175368, and this is of importance in understanding their role in the pathogenesis and as a biomarker for this disease. 30133114

2018

dbSNP: rs10187424
rs10187424
A 0.700 GeneticVariation GWASDB Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. 21743467

2011

dbSNP: rs1024611
rs1024611
0.010 GeneticVariation BEFREE We performed a case-control study to analyze the frequencies of CCL2 (I/D, rs3917887), -2518 (A > G, rs1024611), and CCR2 (G > A, rs1799864) polymorphisms for prostate cancer (PCa) risk. 25266801

2015

dbSNP: rs103294
rs103294
0.730 GeneticVariation BEFREE In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls. 23023329

2012

dbSNP: rs103294
rs103294
C 0.730 GeneticVariation GWASDB In addition to confirming several associations reported in other ancestry groups, this study identified two new risk-associated loci for prostate cancer on chromosomes 9q31.2 (rs817826, P = 5.45 × 10(-14)) and 19q13.4 (rs103294, P = 5.34 × 10(-16)) in 4,484 prostate cancer cases and 8,934 controls. 23023329

2012

dbSNP: rs103294
rs103294
0.730 GeneticVariation BEFREE Three SNPs-rs2735839, rs10486567, and rs103294-were associated with biopsy-proven high-aggressive (GS ≥8) prostate cancer (P < 0.05). 25274378

2014